Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMounjaro can lead to some reduction in muscle mass alongside fat loss, as happens with most significant calorie deficits — but the concern that it "eats muscle" is often overstated. Clinical trial data show the majority of weight lost on tirzepatide is fat tissue, and targeted activity significantly shifts that balance. These are prescription-only medicines assessed individually by a clinician, so how muscle is affected varies from person to person.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
A lot of people starting Mounjaro have read (usually on a forum or a social media thread) that the medicine "burns muscle." It is understandable where the worry comes from. Any treatment that helps you eat substantially less will tend to produce some loss of lean tissue alongside fat. That is true of low-calorie diets generally, not something unique to tirzepatide, which goes by several names you may have come across.
What the evidence does not support is the idea that Mounjaro preferentially targets muscle or causes muscle loss beyond what you would expect from a comparable calorie deficit through other means. The SURMOUNT-1 trial, published in the New England Journal of Medicine, found that most weight lost on tirzepatide at higher doses was fat mass. Lean mass changes were broadly consistent with what other weight-management approaches produce. So the concern is real enough to take seriously, but the framing (that Mounjaro is particularly destructive to muscle) does not hold up. Worth setting down, and moving on.
For a more detailed look at what the research says specifically about lean tissue, our page on how Mounjaro affects muscle mass covers the trial data in depth.
When you lose weight, your body draws energy from both stored fat and some lean tissue. The proportion shifts depending on how fast you lose, how much protein you eat, how active you are, and your baseline body composition. Mounjaro reduces appetite significantly, which is precisely what makes it effective. But a quieter appetite also means it is easy to slip below the protein intake your muscles need to maintain themselves, without feeling hungry at all.
This is where the practical risk sits, and it is manageable. NHS guidance on tirzepatide notes that treatment should be combined with a reduced-calorie diet and increased physical activity, not as a footnote, but because both genuinely change the composition of weight lost. Protein adequacy and resistance training are the two levers you have most control over.
Age also plays a role. Older adults naturally lose lean mass more readily (sarcopenia), so the balance between fat and lean loss deserves closer attention for people in their sixties and beyond. If that applies to you, it is worth raising with your prescriber at consultation.
Some people on tirzepatide do notice muscle-related symptoms. Aching and soreness in the early weeks are sometimes reported, and our page on aching muscles on Mounjaro covers those experiences in detail. Occasional cramps, tiredness, or general fatigue can also occur, often tied to reduced calorie intake rather than the medicine acting directly on muscle tissue.
If you experience significant or persistent muscle weakness, pain that does not settle, or swelling, do not put it down to the treatment without checking. A prescriber should review those symptoms. Unusual pain radiating into the back or abdomen is always a reason to seek medical attention promptly; the MHRA has highlighted acute pancreatitis as an infrequent but serious consideration with GLP-1 medicines, report any suspected side effects at the MHRA's Yellow Card service.
Separately, if you are taking HRT alongside Mounjaro, there is guidance worth being aware of around how tirzepatide can affect the absorption of certain medicines, our page on Mounjaro and HRT sets that out clearly.
Three things have good practical backing for protecting lean mass during weight loss on tirzepatide. First, resistance training, even two sessions a week of bodyweight exercises, weights or resistance bands is meaningfully better than cardio alone for preserving muscle. Second, protein: aim to include a source at each meal, even when appetite is low. Your prescriber or a registered dietitian can give you a personal target, but many people find that consciously building protein into smaller portions makes a real difference. Third, stay well hydrated; nausea-driven low fluid intake can compound fatigue.
If you are considering Mounjaro and want to understand what the assessment process involves, our tirzepatide overview sets out how the medicine works, what the consultation covers, and what to expect in the early weeks. For a broader picture of the weight-loss options a prescriber can assess you for, our weight-loss treatment overview is a useful starting point.
Information about what treatment costs as part of a complete private service is on our Mounjaro pricing page. When you are ready to speak to a prescriber about whether Mounjaro is right for you, you can check your eligibility, consultations are free, and reviewed the same day by a GPhC-registered prescriber.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.